Agenus Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Agenus Inc (AGEN)
Agenus Inc stock price live, this page displays NASDAQ AGEN stock exchange data. View the AGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Agenus Inc real time stock price chart below.
What Is the Agenus Inc Stock Price Today?
The Agenus Inc stock price today is 3.380.
What Is the Stock Symbol for Agenus Inc?
The stock symbol for Agenus Inc is "AGEN."
What Stock Exchange Does Agenus Inc Trade On?
Agenus Inc is listed and trades on the NASDAQ stock exchange.
Is Agenus Inc a Good Stock to Buy?
Determining whether Agenus Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGEN quote. (ISIN: US00847G8042)
What Is the Agenus Inc Stock Price Today?
The Agenus Inc stock price today is 3.380.
What Is the Stock Symbol for Agenus Inc?
The stock symbol for Agenus Inc is "AGEN."
What Stock Exchange Does Agenus Inc Trade On?
Agenus Inc is listed and trades on the NASDAQ stock exchange.
Is Agenus Inc a Good Stock to Buy?
Determining whether Agenus Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGEN quote. (ISIN: US00847G8042)
NASDAQ
Currency in USD
3.380
-0.120(-3.43%)
Closed·
After Hours
3.480+0.110(+3.264%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.201
3.670
52 wk Range
1.380
19.688
AGEN Scorecard
Full Analysis
2 analysts have revised their earnings upwards for the upcoming period
AGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.2013.670
52 wk Range
1.38019.688
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AGEN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
6.000
Upside
+77.51%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Agenus Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Agenus appoints oncology veteran Dr. Goldberg as CDO
- Investing.com
Agenus Inc Company Profile
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Agenus Inc Earnings Call Summary for Q1/2025
- Q1 2025 net loss reduced to $26.4M from $63.5M in Q1 2024; stock rose 9.28% premarket despite financial challenges
- BotBal combination therapy shows promising results across multiple cancer types, positioning Agenus competitively in oncology
- Company aims to cut annual operational cash burn below $50M in H2 2025; exploring strategic collaborations and facility monetization
- Pursuing conditional approval pathways in Europe for therapies; CEO emphasizes urgency of mission in treating young cancer patients
- Financial sustainability remains a concern with declining cash balance; company faces market competition and regulatory hurdles
Last Updated: 2025-05-12, 09:30 a/m
Read Full TranscriptCompare AGEN to Peers and Sector
Metrics to compare | AGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −0.6x | −0.5x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price/Book | −0.3x | 2.6x | 2.6x | |
Price / LTM Sales | 0.9x | 10.3x | 2.9x | |
Upside (Analyst Target) | 100.0% | 341.2% | 50.4% | |
Fair Value Upside | Unlock | 18.5% | 9.1% | Unlock |
Analyst Ratings
1 Buy
4 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 6.000
(+77.51% Upside)
Earnings
Latest Release
Mar 17, 2025
EPS / Forecast
-2.00 / -2.84
Revenue / Forecast
26.84M / 31.15M
People Also Watch
FAQ
What Is the Agenus (AGEN) Stock Price Today?
The Agenus stock price today is 3.38
What Stock Exchange Does Agenus Trade On?
Agenus is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Agenus?
The stock symbol for Agenus is "AGEN."
What Is the Agenus Market Cap?
As of today, Agenus market cap is 95.96M.
What Is Agenus's Earnings Per Share (TTM)?
The Agenus EPS (TTM) is -10.59.
From a Technical Analysis Perspective, Is AGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.